Paper3085702
Lack of correlation between antitumour response and serum interferon levels in mice treated with SSM, an immunotherapeutic anticancer agent.
Suzuki F and 2 others. Br J Cancer, 1986. Cited by 7 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Lack of correlation between antitumour response and serum interferon levels in mice treated with SSM, an immunotherapeutic anticancer agent. Papers, record 3085702. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3085702
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lack of correlation between antitumour response and serum interferon levels in mice treated with SSM, an immunotherapeutic anticancer agent.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Biological Products | Major topic |
| Carcinoma, Ehrlich Tumor | Major topic |
| Interferon-gamma | Major topic |
| Leukemia, Experimental | Major topic |
| Lipids | Major topic |
| Mannans | Major topic |
| Animals | |
| Immunotherapy | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Time Factors |
Source PubMed
References8
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5,639,157 | Absence of thymus in a mouse mutant. | Nature | 1968 | https://conductscience.org/library/papers/5639157 | PubMed |
| 2 | 4,100,989 | Observations on the immunobiology of 'nude' mice. | Immunology | 1971 | https://conductscience.org/library/papers/4100989 | PubMed |
| 3 | 374,263 | In vitro production and cellular origin of murine type II interferon. | Immunology | 1979 | https://conductscience.org/library/papers/374263 | PubMed |
| 4 | 7,151,063 | Collagen and stromal proliferation as preventive mechanisms against cancer invasion by purified polysaccharides from human tubercle bacillus (SSM). | Cancer Detect Prev | 1982 | https://conductscience.org/library/papers/7151063 | PubMed |
| 5 | 6,789,037 | Interferon-inducing activity of an immunotherapeutic anticancer agent, SSM, prepared from Mycobacterium tuberculosis strain Aoyama B. | Microbiol Immunol | 1981 | https://conductscience.org/library/papers/6789037 | PubMed |
| 6 | 6,799,639 | [Studies on hot water extract of Mycobacterium tuberculosis. I. Structural analyses of polysaccharides (author's transl)]. | Yakugaku Zasshi | 1981 | https://conductscience.org/library/papers/6799639 | PubMed |
| 7 | 6,214,578 | Mechanism for the suppression of gamma-interferon responsiveness in mice after thermal injury. | J Immunol | 1982 | https://conductscience.org/library/papers/6214578 | PubMed |
| 8 | 6,767,175 | The induction of viral inhibitor(s) in mice treated with biological and synthetic immunopotentiators. | Microbiol Immunol | 1980 | https://conductscience.org/library/papers/6767175 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 2,480,846 | Stimulation of non-specific resistance to tumors in the mouse using a poly(maleic-acid-styrene)-conjugated neocarzinostatin. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2480846 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3085702
GET https://conductscience.org/api/papers/v1/3085702/authors